Weight-loss jabs could 'slow down the clock' on biological ageing

Recent studies suggest that weight-loss injections, particularly semaglutide (known as Ozempic or Wegovy), may have significant benefits beyond weight loss, potentially slowing biological aging. Presented at the European Society of Cardiology conference, research indicates that semaglutide can reduce inflammation in the body, which is linked to various diseases such as cancer, arthritis, Alzheimer’s, and Parkinson’s. Trials from institutions like Yale and Harvard show that semaglutide can reverse kidney disease, prevent heart failure, and lower the risk of severe COVID-19 outcomes. Experts advocate for its broader use as a multi-purpose drug that enhances overall health, not just as an anti-obesity treatment. However, while the drug shows promise, it is not effective for everyone and can cause severe side effects, including pancreatitis and bowel obstruction. The findings highlight the potential of semaglutide to target diseases associated with aging, but experts caution that more research is needed to fully understand its mechanisms and long-term effects.

- Semaglutide may slow biological aging by reducing inflammation.

- It has shown effectiveness in treating various health conditions beyond weight loss.

- The drug could potentially replace other medications for heart disease and high blood pressure.

- Side effects include severe conditions like pancreatitis and bowel obstruction.

- Further research is necessary to understand the long-term implications of semaglutide use.